News | 02 June 2023
Evonik launches next-generation peptide for biopharma applications
One thousand times more soluble than L-cystine at neutral pH
One thousand times more soluble than L-cystine at neutral pH
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
The PP-based top and bottom webs are manufactured in a unique coextrusion process
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
